December 16, 2024

Colon Cancer's Hidden Inflammatory Signature Found

Researchers have identified a significant breakdown in the body's natural inflammation-resolution process in colorectal cancer, where tumor cells maintain a chronic inflammatory state by failing to switch from pro-inflammatory to inflammation-resolving lipids, potentially opening new therapeutic pathways.

Conexiant

December 13, 2024

MTAP Deficiency: A New Biomarker and Therapeutic Target in Aggressive Urothelial Bladder Cancer

With MTAP loss predictive of worse outcomes, researchers explore precision therapies and diagnostic advancements in bladder cancer.

Conexiant

December 11, 2024

Colectomy Raises AKI, Kidney Failure Risk in IBD

A recent study has revealed that patients with inflammatory bowel disease face elevated risks of acute kidney injury and chronic kidney failure after undergoing colectomy, with certain factors increasing these risks. Read more about the study in Clinical Gastroenterology and Hepatology.

Conexiant

December 06, 2024

ABSI vs. BMI: Predicting CRC Risk in Metabolic Syndrome

New study reveals that A Body Shape Index (ABSI) outperforms traditional measures in predicting colorectal cancer risk among individuals with metabolic syndrome.

Conexiant

December 02, 2024

2024 Vitamin D Guidelines: A Critical Review

"If the pharmaceutical industry had developed a single drug capable of reducing cancer mortality by 25%, autoimmune disorders by 39%, and COVID-19 infection rates by 74%, it would be heralded as a miracle drug."

Conexiant

May 02, 2024

New NCI Grant to Foster Development of Novel Therapy in Metastatic Colorectal Cancer

The Case Western Reserve University School of Medicine received a 5-year $1.84 million grant to investigate the role of the LRG1 protein in colorectal cancer growth and develop a novel treatment option for patients with metastatic colorectal cancer.

Conexiant

May 02, 2024

AACR 2024: Adagrasib Plus Cetuximab in KRAS G12C–Mutated Colorectal Cancer

The combination of adagrasib and cetuximab may show clinical activity and promising survival outcomes in patients with metastatic, heavily pretreated, KRAS G12C–mutated colorectal cancer.

Conexiant

March 24, 2023

Studies of Novel Therapeutic Approaches Highlighted During Colorectal Cancer Awareness Month at Dana-Farber

The rise of colorectal cancer in those under 50 has spurred reevaluation of screening guidelines. Dr. Benjamin Schlechter is pioneering studies to explore novel treatment options, including next-generation immunotherapy drugs and CAR T-cell therapy, showing promising clinical activity.

The ASCO Post

May 22, 2024

DDW: Adjuvant Therapy May Improve Rectal Adenocarcinoma Survival

Adjuvant therapy may be underutilized in patients with clinical T2N0 rectal adenocarcinoma, according to new findings presented at Digestive Disease Week 2024.

Conexiant